These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 30896884)
1. Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation. Xiao Z; He Y; Liu C; Xiang L; Yi J; Wang M; Shen T; Shen L; Xue Y; Shi H; Liu P Oncol Rep; 2019 May; 41(5):2667-2678. PubMed ID: 30896884 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483 [No Abstract] [Full Text] [Related]
3. KDM6B promotes ESCC cell proliferation and metastasis by facilitating C/EBPβ transcription. Qin M; Han F; Wu J; Gao FX; Li Y; Yan DX; He XM; Long Y; Tang XP; Ren DL; Gao Y; Dai TY BMC Cancer; 2021 May; 21(1):559. PubMed ID: 34001062 [TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Hashizume R; Andor N; Ihara Y; Lerner R; Gan H; Chen X; Fang D; Huang X; Tom MW; Ngo V; Solomon D; Mueller S; Paris PL; Zhang Z; Petritsch C; Gupta N; Waldman TA; James CD Nat Med; 2014 Dec; 20(12):1394-6. PubMed ID: 25401693 [TBL] [Abstract][Full Text] [Related]
5. Expression and effects of JMJD2A histone demethylase in endometrial carcinoma. Wang HL; Liu MM; Ma X; Fang L; Zhang ZF; Song TF; Gao JY; Kuang Y; Jiang J; Li L; Wang YY; Li PL Asian Pac J Cancer Prev; 2014; 15(7):3051-6. PubMed ID: 24815446 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia. Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337 [TBL] [Abstract][Full Text] [Related]
7. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription. Zheng Q; Fan H; Meng Z; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):897-904. PubMed ID: 30060056 [TBL] [Abstract][Full Text] [Related]
8. GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells. Yan N; Xu L; Wu X; Zhang L; Fei X; Cao Y; Zhang F Exp Cell Res; 2017 Oct; 359(2):405-414. PubMed ID: 28823831 [TBL] [Abstract][Full Text] [Related]
9. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. Sarfstein R; Friedman Y; Attias-Geva Z; Fishman A; Bruchim I; Werner H PLoS One; 2013; 8(4):e61537. PubMed ID: 23620761 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Mathur R; Sehgal L; Havranek O; Köhrer S; Khashab T; Jain N; Burger JA; Neelapu SS; Davis RE; Samaniego F Haematologica; 2017 Feb; 102(2):373-380. PubMed ID: 27742770 [TBL] [Abstract][Full Text] [Related]
11. KDM6B-mediated histone demethylation of LDHA promotes lung metastasis of osteosarcoma. Jiang Y; Li F; Gao B; Ma M; Chen M; Wu Y; Zhang W; Sun Y; Liu S; Shen H Theranostics; 2021; 11(8):3868-3881. PubMed ID: 33664867 [No Abstract] [Full Text] [Related]
12. Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma. Theisen ER; Gajiwala S; Bearss J; Sorna V; Sharma S; Janat-Amsbury M BMC Cancer; 2014 Oct; 14():752. PubMed ID: 25300887 [TBL] [Abstract][Full Text] [Related]
13. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. Schwab CL; Bellone S; English DP; Roque DM; Lopez S; Cocco E; Nicoletti R; Bortolomai I; Bonazzoli E; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD Br J Cancer; 2014 Oct; 111(9):1750-6. PubMed ID: 25268372 [TBL] [Abstract][Full Text] [Related]
14. p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. Semczuk A; Boltze C; Marzec B; Szczygielska A; Roessner A; Schneider-Stock R J Cancer Res Clin Oncol; 2003 Oct; 129(10):589-96. PubMed ID: 12920579 [TBL] [Abstract][Full Text] [Related]
15. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627 [TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines. McLaughlin-Drubin ME; Park D; Munger K Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16175-80. PubMed ID: 24046371 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic inactivation of EFEMP1 is associated with tumor suppressive function in endometrial carcinoma. Yang T; Qiu H; Bao W; Li B; Lu C; Du G; Luo X; Wang L; Wan X PLoS One; 2013; 8(6):e67458. PubMed ID: 23840707 [TBL] [Abstract][Full Text] [Related]
18. Histone demethylase KDM6B regulates 1,25-dihydroxyvitamin D3-induced senescence in glioma cells. Sui A; Xu Y; Pan B; Guo T; Wu J; Shen Y; Yang J; Guo X J Cell Physiol; 2019 Aug; 234(10):17990-17998. PubMed ID: 30825201 [TBL] [Abstract][Full Text] [Related]
19. KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1. Qiu MT; Fan Q; Zhu Z; Kwan SY; Chen L; Chen JH; Ying ZL; Zhou Y; Gu W; Wang LH; Cheng WW; Zeng J; Wan XP; Mok SC; Wong KK; Bao W Oncotarget; 2015 Oct; 6(31):31702-20. PubMed ID: 26397136 [TBL] [Abstract][Full Text] [Related]
20. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. Black J; Menderes G; Bellone S; Schwab CL; Bonazzoli E; Ferrari F; Predolini F; De Haydu C; Cocco E; Buza N; Hui P; Wong S; Lopez S; Ratner E; Silasi DA; Azodi M; Litkouhi B; Schwartz PE; Goedings P; Beusker PH; van der Lee MM; Timmers CM; Dokter WH; Santin AD Mol Cancer Ther; 2016 Aug; 15(8):1900-9. PubMed ID: 27256376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]